Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial

Evaluation of Cinacalcet HCL Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators

Publikation: Beitrag in FachzeitschriftArtikelBegutachtung

263 Zitate (Scopus)

Fingerprint

Untersuchen Sie die Forschungsthemen von „Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial“. Zusammen bilden sie einen einzigartigen Fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science